Immunomedics Inc.’s (IMMU) Biologics License Application for Sacituzumab govitecan, which is under priority review by the FDA, has a decision date of January 18, 2019. Sacituzumab govitecan is proposed for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who previously received at least two prior treatments.Triple negative breast cancer is a type of breast cancer whose cells don’t have receptors for the hormones oestrogen and progesterone, and protein Her2. It is said to be more aggressive and difficult to treat.Also known as IMMU-132, Sacituzumab govitecan is a novel first-in-class antibody-drug conjugate (ADC) that delivers a lethal payload of moderately-toxic chemotherapeutic SN-38 to TROP-2-expressing cells. Trop-2 is a cell-surface glycoprotein expressed on more than 90% of triple-negative tumors. If approved, Sacituzumab govitecan would be the first and only ADC approved for the treatment of metastatic triple-negative breast cancer.IMMU closed Friday’s (Dec.21, 2018) trading at $15.04, up 6.14%.